2026年ASCO胃肠道肿瘤研讨会（ASCO GI）将于2026年1月8~10日在美国旧金山召开，目前大会官网已公布所有摘要标题，包括了备受瞩目的LBA（Late-Breaking Abstract）研究。本次大会涵盖食管癌、胃癌、肝胆胰肿瘤、结直肠癌及肛门癌等消化道肿瘤领域的最新研究成果。值得关注的是，从最新公布的标题来看，多个免疫、靶向药物的关键III期数据，以及多项中国专家主导的PD-1/PD-L1联合治疗研究成果将成为本次会议的焦点，有望改写未来的临床诊疗指南。【肿瘤资讯】特此整理了口头报告标题，以飨诸君。
Oral Abstract Session A: Cancers of the Esophagus and Stomach
（口头摘要专场A：食管癌和胃癌）
摘要号：282
英文标题：Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial.
中文标题：围手术期特瑞普利单抗联合化疗对比单纯化疗治疗局部晚期胃或胃食管交界处癌：前瞻性、随机、II期NEOSUMMIT-01试验的3年随访结果
讲者：袁庶强
医院：中山大学肿瘤防治中心
摘要号：283
英文标题：CRITICS-II: A multicenter randomized phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
中文标题：CRITICS-II：在可切除胃癌中比较“新辅助化疗序贯手术”、“新辅助化疗序贯放化疗后手术”与“新辅助放化疗序贯手术”的多中心、随机II期试验
讲者：Marcel Verheij
医院：Radboud大学医学中心
摘要号：LBA284
英文标题：Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
中文标题：佐妥昔单抗联合mFOLFOX6及纳武利尤单抗一线治疗CLDN18.2阳性局部晚期不可切除或转移性胃或胃食管交界处（mG/GEJ）腺癌患者的II期ILUSTRO试验
讲者：Kohei Shitara
医院：国立癌症中心东病院
摘要号：LBA285
英文标题：Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): First results from the phase 3 HERIZON-GEA-01 study.
中文标题：泽尼达妥单抗联合化疗±替雷利珠单抗一线治疗HER2阳性晚期/转移性胃食管腺癌：III期HERIZON-GEA-01研究首次结果
讲者：Elena Elimova
医院：玛格丽特公主癌症中心
Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
（快速口头摘要专场A：食管癌和胃癌）
摘要号：286
英文标题：Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase IIb study (TERRIFIC).
中文标题：替雷利珠单抗联合放化疗对比放化疗或化疗新辅助治疗局部晚期胃/胃食管交界处腺癌患者：一项多中心、随机对照、开放标签IIb期研究（TERRIFIC）
讲者：魏嘉
医院：南京大学医学院附属鼓楼医院
摘要号：LBA287
英文标题：Liposomal irinotecan, carboplatin or oxaliplatin (LyRICX) with or without nivolumab in the first-line treatment of metastatic or irresectable esophagogastric adenocarcinoma: A randomized phase 2 study.
中文标题：脂质体伊立替康、卡铂或奥沙利铂（LyRICX）联合或不联合纳武利尤单抗一线治疗转移性或不可切除食管胃腺癌：一项随机II期研究
讲者：Denice Kamp
摘要号：288
英文标题：Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial.
中文标题：胃或胃食管交界处腺癌患者ECOG体能状态与患者报告结局（PROs）之间的关联：来自RATIONALE-305试验的结果
讲者：Marcia Roxana Cruz-Correa
摘要号：289
英文标题：Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial.
中文标题：奥沙利铂联合S-1（SOX）对比S-1辅助治疗II-III期胃或胃食管交界处腺癌患者（CAPITAL）：一项随机、开放标签III期试验。
讲者：聂润聪
医院：中山大学肿瘤防治中心
摘要号：290
英文标题：Effect of exercise and nutritional prehabilitation on preoperative lean body mass in elderly gastric cancer patients: Results of a randomized controlled trial.
中文标题：运动和营养预康复对老年胃癌患者术前瘦体重的影响：一项随机对照试验的结果
讲者：Kazuyoshi Yamamoto
医院：大阪国际癌症研究所
摘要号：291
英文标题：SOX (tegafur plus oxaliplatin) plus anti-PD-1 antibody with or without CAR-like T cell immunotherapy in the treatment of patients with previously untreated metastatic gastric cancer/gastroesophageal junction adenocarcinoma: A multicenter, open-label, randomized, controlled, phase II trial.
中文标题：SOX（tegafur联合奥沙利铂）联合抗PD-1抗体±CAR-like T细胞免疫疗法治疗初治转移性胃癌/胃食管交界处腺癌患者：一项多中心、开放标签、随机对照、II期试验。
讲者：Qin Liu
医院：南京大学医学院附属鼓楼医院
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
（口头摘要专场B：胰腺、小肠和肝胆肿瘤）
摘要号：476
英文标题：Efficacy and safety of lirafugratinib in FGFRi-naive cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2 f/r).
中文标题：Lirafugratinib在携带FGFR2融合/重排的FGFR抑制剂初治胆管癌患者中的疗效和安全性
讲者：Antoine Hollebecque
医院：Gustave Roussy癌症研究所
摘要号：654
英文标题：Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
中文标题：新型口服KRAS G12D抑制剂INCB161734单药或联合化疗治疗晚期/转移性胰腺导管腺癌的I期研究初步结果
讲者：Zev A. Wainberg
医院：大卫·格芬医学院
摘要号：477
英文标题：Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.
中文标题：帕博利珠单抗辅助治疗手术切除或局部消融后达到影像学完全缓解的肝细胞癌患者：III期KEYNOTE-937研究
讲者：Stephen Lam Chan
医院：香港中文大学临床肿瘤学系
摘要号：478
英文标题：IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
中文标题：IKF-035/ABC-HCC：一项比较阿替利珠单抗联合贝伐珠单抗对比经动脉化疗栓塞（TACE）治疗中期肝细胞癌的IIIb期、随机、多中心、开放标签试验
讲者：Peter Robert Galle
Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
（快速口头摘要专场B：胰腺、小肠和肝胆肿瘤）
摘要号：653
英文标题：Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
中文标题：Elraglusib联合吉西他滨/白蛋白结合型紫杉醇（GnP）对比GnP治疗初治转移性胰腺导管腺癌的随机II期研究（1801 Part 3B）结果
讲者：Devalingam Mahalingam
摘要号：655
英文标题：Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).
中文标题：派安普利单抗（PD-1抑制剂）、安罗替尼（抗血管生成靶向药）、白蛋白结合型紫杉醇和吉西他滨联合作为转移性胰腺癌的一线治疗方案：一项多中心、随机对照试验（RCT-PAAG）
讲者：Juan Du
医院：南京大学医学院附属鼓楼医院
摘要号：LBA479
英文标题：Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.
中文标题：纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼一线治疗不可切除肝细胞癌：CheckMate 9DW研究的4年随访结果
讲者：Peter Robert Galle
摘要号：724
英文标题：Phase II study of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair genes alterations.
中文标题：度伐利尤单抗联合olaparib治疗伴有DNA损伤修复基因改变的转移性胰腺癌患者的II期研究
讲者：Teresa Macarulla
医院：Valld'Hebron大学医院
摘要号：728
英文标题：ALTOPANC: Local ablative therapies in oligometastatic pancreatic adenocarcinoma—A bi-national French-Belgian retrospective study.
中文标题：ALTOPANC：寡转移性胰腺腺癌的局部消融治疗——一项法国-比利时两国回顾性研究
讲者：Anthony Turpin
Rapid Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
（快速口头摘要专场C：结直肠癌和肛门癌）
摘要号：17
英文标题：FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC).
中文标题：FOxTROT：ERBB2和ERBB3对RAS/BRAF野生型局部晚期结肠癌新辅助帕尼单抗治疗获益的预测作用
讲者：Jordan Wesley Appleyard
摘要号：18
英文标题：GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.
中文标题：GLP-1受体激动剂对比阿司匹林用于结直肠癌的一级预防：来自真实世界头对头比较的证据
讲者：Colton Jones
医院：德克萨斯大学圣安东尼奥分校
摘要号：19
英文标题：Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data.
中文标题：解码早发性（<50岁）与晚发性（≥50岁）错配修复缺陷（dMMR）/微卫星高度不稳定（MSI-H）结直肠癌在分子、临床病理和预后方面的差异：来自真实世界数据的见解
讲者：Michela Bartolini
医院：南加州大学Keck医学院诺里斯综合癌症中心
摘要号：20
英文标题：Liver transplantation for unresectable colorectal liver metastases: Pooled real-world data from all Belgian liver transplant centers.
中文标题：肝移植治疗不可切除结直肠癌肝转移：来自比利时所有肝移植中心的真实世界汇总数据
讲者：Gertjan Rasschaert
医院：鲁汶大学医院
摘要号：1
英文标题：Early outcomes of the PLATO ACT5 randomised trial: Personalizing anal cancer radiotherapy dose.
中文标题：PLATO ACT5随机试验的早期结果：肛门癌放疗剂量的个体化
讲者：Maria A Hawkins
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
（口头摘要专场C：结直肠癌和肛门癌）
摘要号：13
英文标题：BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
中文标题：BREAKWATER：康奈非尼+西妥昔单抗（EC）+FOLFIRI一线治疗BRAF V600E突变转移性结直肠癌的主要分析
讲者：Scott Kopetz
医院：德克萨斯大学MD安德森癌症中心
摘要号：14
英文标题：Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.
中文标题：dMMR转移性结直肠癌免疫治疗研究（COMMIT）：一项比较阿替利珠单抗单药对比mFOLFOX6+贝伐珠单抗+阿替利珠单抗一线治疗dMMR/MSI-H转移性结直肠癌患者的随机III期研究（NRG-GI004/SWOG-S1610）
讲者：Caio Max Sao Pedro Rocha Lima
摘要号：15
英文标题：Diffusion-weighted magnetic resonance imaging versus surgical staging in patients with colorectal peritoneal metastases: The multicenter, international, randomized controlled DISCO trial.
中文标题：弥散加权磁共振成像对比手术分期用于结直肠癌腹膜转移患者：多中心、国际、随机对照DISCO试验
讲者：Lizzel van der Snee
医院：荷兰癌症研究所
摘要号：16
英文标题：Longitudinal study on the influence of physical activity in managing cancer-related fatigue in patients with colorectal cancer.
中文标题：身体活动对结直肠癌患者癌因性疲乏管理影响的纵向研究
讲者：Louisa Liu, MD
医院：Cedars-Sinai医疗中心
排版编辑：肿瘤资讯-as
苏公网安备32059002004080号
